As reported by Pharmatimes,
“The six-month consultation, on proposals to regularise NICE’s decision-making process through value-based assessment, has produced no agreement among the more than 900 opinions received from 121 organisations and individuals, and it is clear that just changing NICE’s methods will not overcome concerns about how the NHS accesses new treatments”
Details are still sketchy from the NICE public board meeting where VBA was discussed. No press release or Board minutes, as yet. The only response to date appears to be from the ABPI who have reiterated what the pharmaceutical industry considers to an appropriate way to spend tax payers’ money.
What next?
